Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

N-acetylcysteine for Attenuation of COVID Symptomatology

NCT05074121 is registered in ClinicalTrials.gov with Cambridge Health Alliance as lead sponsor.

NCT NCT05074121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05074121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
N-acetylcysteine for Attenuation of COVID Symptomatology
Lead sponsor
Cambridge Health Alliance
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2024
Completion date
February 1, 2025
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 lower respiratory infection, covid-19 pneumonia, covid-19 respiratory infection, covid19, oxidative stress, sars-associated coronavirus as cause of disease classified elsewhere, sars-cov-2 acute respiratory disease, sars-cov2 infection